Evogene Officially Opens Research and Development Facility in St. Louis, Missouri
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Evogene Ltd. (EVGN) Expects Delayed Evofuel commercialization; Piper Jaffray Cuts Price Target to $8
November 19, 2015 8:56 AM ESTPiper Jaffray reiterated a Neutral rating on Evogene Ltd (NYSE: EVGN), and cut the price target to $8.00 (from $12.00), following the company's 3Q earnings report .Evogene announced results relatively in-line with Piper Jaffray's expectations, where revenue and opex were only slightly higher due to more gene discovery being done in-house. Management now expects Evofuel commercialization to be delayed,... More
